Overall, patients in the semaglutide arm had a median improvement in walking distance of 26 meters and an average improvement of 40 meters, representing a statistically significant 13% improvement ...

Overall, patients in the semaglutide arm had a median improvement in walking distance of 26 meters and an average improvement of 40 meters, representing a statistically significant 13% improvement ...

Additionally, the trial met all secondary endpoints, demonstrating significant improvement with semaglutide vs placebo in pain-free walking distance (ETR: 1.11 [95% CI, 1.03-1.20; P =.0046 ...

Overall, patients in the semaglutide arm had a median improvement in walking distance of 26 meters and an average improvement of 40 meters, representing a statistically significant 13% improvement ...

The double-blind, randomised, placebo-controlled STRIDE trial achieved its primary endpoint, with semaglutide 1.0 mg demonstrating a superior and clinically meaningful improvement of 13% in maximum ...

Compared with placebo, the semaglutide group had a median improvement in maximum walking distance from baseline to 52 weeks of 26.4 m (95% CI, 11.8-40.9); mean improvement was 39.9 m (95% CI ...

And the mean improvement in walking distance in the semaglutide group was approximately 40 meters," Bonaca reported. An improvement of 20 meters on a flat surface would be considered clinically ...

Overall, patients in the semaglutide arm had median and mean improvements in walking distance compared to placebo of 26 meters and 39.9 meters respectively, giving a statistically significant ...

with semaglutide 1.0 mg demonstrating a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline ...